BG-C137 / BeOne Medicines - LARVOL DELTA

A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=68 | Not yet recruiting | Sponsor: BeiGene

New P1 trial • Oncology • Solid Tumor

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=168 | Recruiting | Sponsor: BeOne Medicines | N=68 ➔ 168

Enrollment change • First-in-human • Oncology • Solid Tumor

A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=68 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Engineering and development of a novel bispecific ADC targeting EGFR and FGFR2b (AACR 2026) - "Bemarituzumab, an afucosylated FGFR2b monoclonal antibody has shown efficacy in the clinical study for the treatment in patients with FGFR2b‑positive GC and GEJ cancer...Our EGFR×FGFR2b bsAb function as a partial FGFR2b ligand blocker, and only weakly inhibiting FGF7 while sparing FGF10‑mediated signaling, thus with the potential to reduce on‑target toxicity associated with FGF7/FGF10 blockade. Several bsAb ADC were generated with various cytotoxic payloads and are being tested in vitro and in vivo studies."

ADC • Bispecific • Gastric Cancer • Oncology • Solid Tumor • EGFR • FGF10 • FGF7 • FGFR2

Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b-targeting ADC, for the treatment of FGFR2b-expressing cancer (AACR 2025) - P1 | "Indeed, the clinical benefit of targeting FGFR2b has been demonstrated by Bemarituzumab, an Fc-enhanced monoclonal antibody in combination with chemotherapy in first-line FGFR2b-expressing gastric cancer. With its differentiated targeting strategy, BG-C137 is not only a first-in-class FGFR2b ADC but also holds the potential to pursue the best-in-class opportunity in FGFR2b targeting treatments. Together, these observations support the clinical development of BG-C137 for the treatment of FGFR2b-expressing tumors (ClinicalTrials.gov ID NCT06625593)."

ADC • Preclinical • Gastric Cancer • Oncology • Solid Tumor • FGFR2

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Update (Businesswire) - "Anticipate...internal proof-of-concept data for BG-60366 (EGFR CDAC), BGB-53038 (panKRAS inhibitor), BG-C137 (FGFR2b ADC), BGB-C354 (B7H3 ADC), and BG-C477 (CEA ADC) in the second half of 2025."

P1 data • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates (Businesswire) - "BGB-16673 (BTK CDAC): Anticipate initiation of Phase 3 trial in R/R CLL in the first half of 2025; NMEs on track to enter the clinic in the fourth quarter of 2024...BGB-53038 (PanKRAS inhibitor): highly potent and selective with broad activity against KRAS mutations in multiple tumor types; limits toxicity by sparing other RAS proteins and BG-C137 (FGFR2b ADC): potential first-in-class ADC for a validated target in upper gastrointestinal and breast cancers; potential superior efficacy compared to leading monoclonal antibody in both high- and medium-expression models."

New P3 trial • New trial • Breast Cancer • Chronic Lymphocytic Leukemia • Gastrointestinal Cancer